FGFR2 and neoplasm: The following tumor mutations were reported in patients with clinical benefit: cKIT (n = 1), CSF-1R (n = 1), PDGFRα (n = 2), PDGFRβ (n = 1), VEGFR1 (n = 1), VEGFR2 (n = 2), FLT3 (n = 1), FGFR2 (n = 2), RET (n = 1), and TrkA (n = 1).